A new drug called darexonrasib for the treatment of advanced pancreatic cancer has shown encouraging results in a clinical trial when used with chemotherapy, with one in 12 patients achieving complete remission of their tumors.
The study presented in Barcelona showed that the combination of the drug and chemotherapy improved survival rates after one year compared with standard treatment.
In 60.7% of the patients in the study, their tumors shrank or disappeared completely, while in 8.2% of the patients, their tumors became completely undetectable.
The study found that 90.2% of the 61 patients had their tumors stop growing. These results were obtained over a follow-up period of about 18 months.
The drug targets the mutated KRAS gene, which is found in more than 90% of pancreatic cancers.
According to experts, these results may be the closest thing to a complete cure for some patients, but at present it cannot be considered a definitive cure for cancer.
